Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
作者信息
Gemmill J D, Sandler M, Hillis W S, Tillman J, Wakeel R
出版信息
Br Heart J. 1988 Oct;60(4):361. doi: 10.1136/hrt.60.4.361.
Abstract
摘要
相似文献
1
Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.急性心肌梗死患者静脉注射氨甲环酸纤溶酶原链激酶激活剂复合物治疗并发血管炎
Br Heart J. 1988 Oct;60(4):361. doi: 10.1136/hrt.60.4.361.
2
Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.急性心肌梗死患者静脉注射茴香酰化纤溶酶原链激酶激活剂复合物治疗并发血管炎
Br Heart J. 1988 Jan;59(1):9-11. doi: 10.1136/hrt.59.1.9.
3
Comparison of the safety and tolerance of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.急性心肌梗死中静脉注射茴香酰化纤溶酶原链激酶激活剂复合物与冠状动脉内注射链激酶的安全性及耐受性比较。
Drugs. 1987;33 Suppl 3:279-81. doi: 10.2165/00003495-198700333-00052.
4
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Tolerance data.在一家地区医院用茴香酰化纤溶酶原链激酶激活剂复合物治疗急性心肌梗死。耐受性数据。
Drugs. 1987;33 Suppl 3:286. doi: 10.2165/00003495-198700333-00054.
5
Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.茴香酰化纤溶酶原链激酶激活剂复合物与链激酶在急性心肌梗死患者中的安全性及副作用。IRS II研究中期报告。
Drugs. 1987;33 Suppl 3:282-5. doi: 10.2165/00003495-198700333-00053.
6
Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Drugs. 1987;33 Suppl 3:276-8. doi: 10.2165/00003495-198700333-00051.
7
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Efficacy data.在地区医院使用茴香酰化纤溶酶原链激酶激活剂复合物治疗急性心肌梗死。疗效数据。
Drugs. 1987;33 Suppl 3:221-2. doi: 10.2165/00003495-198700333-00038.
8
Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.急性心肌梗死患者静脉注射氨甲环酸纤溶酶原激活剂复合物与冠状动脉内注射链激酶多中心试验中的耐受性和并发症
Clin Cardiol. 1990 Mar;Suppl 5:V11-4; discussion V27-32. doi: 10.1002/clc.4960131304.
9
Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results.茴香酰化纤溶酶原链激酶激活剂复合物在急性心肌梗死中的疗效与安全性评估：初步结果
Drugs. 1987;33 Suppl 3:186-8. doi: 10.2165/00003495-198700333-00032.
10
Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
Drugs. 1987;33 Suppl 3:124-32. doi: 10.2165/00003495-198700333-00020.
本文引用的文献
1
Identification of patients at risk for anaphylaxis due to streptokinase.
Arch Intern Med. 1986 Feb;146(2):305-7.
2
The incidence of monoclonal gammopathy in a population over 45 years old determined by isoelectric focusing.通过等电聚焦法测定45岁以上人群中单克隆丙种球蛋白病的发病率。
Br J Haematol. 1986 Dec;64(4):745-50. doi: 10.1111/j.1365-2141.1986.tb02236.x.
3
Crescentic glomerulonephritis: a possible complication of streptokinase treatment for myocardial infarction.新月体性肾小球肾炎：心肌梗死溶栓治疗的一种可能并发症。
Br Heart J. 1986 Nov;56(5):483-5. doi: 10.1136/hrt.56.5.483.
4
Hypersensitivity vasculitis associated with streptokinase.
Aust N Z J Med. 1986 Dec;16(6):815-6. doi: 10.1111/j.1445-5994.1986.tb00050.x.
Zotero 插件